Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Price Down 32.6% – Should You Sell?

Shares of Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) traded down 32.6% on Thursday . The company traded as low as $0.3571 and last traded at $0.3571. 104 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 408 shares. The stock had previously closed at $0.5295.

Mosaic ImmunoEngineering Stock Performance

The firm has a market capitalization of $2.59 million, a PE ratio of -3.97 and a beta of -0.76. The firm’s 50-day moving average is $0.48 and its 200 day moving average is $0.57.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last announced its earnings results on Wednesday, November 19th. The company reported ($0.02) earnings per share (EPS) for the quarter.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.